Last reviewed · How we verify
NCT03520946: RAMTAS
RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients
Phase 3 trial testing Ramucirumab in Colorectal Cancer in 430 participants. Completed in 30 July 2024.
30 July 2024
Quick facts
| Lead sponsor | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 430 |
| Start date | 24 January 2019 |
| Primary completion | 30 July 2024 |
| Estimated completion | 30 July 2024 |
| Sites | 28 locations across Germany |
Drugs / interventions tested
- Ramucirumab (RAMUCIRUMAB) — full drug profile →
- TAS 102 — full drug profile →
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest — full company profile →
Who can join
18 and older, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Interventional, prospective, randomized (1:1), controlled, open label, multicenter phase IIb study in patients with advanced metastatic colorectal cancer. The scope of the trial is to evaluate overall survival of either regimen (TAS102 +/- Ramucirumab) and evaluate safety and tolerability.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond.
Al Bitar S, El-Sabban M, Doughan S, Abou-Kheir W. · · 2023 · cited 53× · PMID 36998426 · DOI 10.3748/wjg.v29.i9.1395 -
Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer.
Jin KT, Chen B, Liu YY, Lan HU, et al · · 2021 · cited 30× · PMID 33522929 · DOI 10.1186/s12935-021-01763-9 -
Encoding and display technologies for combinatorial libraries in drug discovery: The coming of age from biology to therapy.
Fan Y, Feng R, Zhang X, Wang ZL, et al · · 2024 · cited 22× · PMID 39220863 · DOI 10.1016/j.apsb.2024.04.006 -
Long-Term Progression-Free Survival of a Pre-Treated Patient with Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil.
Michl GM, Vogt FM, Nouriani A, Ladurner R, et al · · 2024 · PMID 37336201 · DOI 10.1159/000531525
Verify or expand the search:
- PubMed search for NCT03520946
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ramucirumab
Trials testing the same drug.
- NCT06996782 — A Platform Study in Non-Small Cell Lung Cancer (NSCLC) · Phase 1, PHASE2 · recruiting
- NCT06675136 — Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal · Phase 1 · recruiting
- NCT07098338 — A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) · Phase 2 · recruiting
- NCT06616584 — Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had · Phase 2, PHASE3 · recruiting
- NCT06771622 — Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · active not recruiting
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest trials
Trials by the same sponsor.
- NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07510724 — Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab · recruiting
- NCT07365930 — NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy · recruiting
- NCT06856837 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma · Phase 2 · recruiting
- NCT06731803 — Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Re · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03520946 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Last refreshed: 9 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03520946.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing